A-139 Investigating the Utility of Reticulocyte Hemoglobin Equivalent for Diagnosis of Iron Deficiency Anemia

Abstract Background Iron deficiency anemia (IDA) is one of the most common leading global health problems, which could cause extreme fatigue, chest pain, headache, and even neurodevelopment deterioration in children. Traditionally, assessing serum ferritin, transferrin, iron are tools to diagnose IDA. However, a high false-positive rate these conventional biomarkers might be observed due inflammation, infection, or malignancy. Reticulocyte hemoglobin equivalent (RET-He) new parameter that reflects recent functional availability for erythropoiesis, with advantage real-time results as part automated reticulocyte analysis. The present study, therefore, aimed investigate utility RET-He diagnosis patients Methods This retrospective study collected laboratory data from both ferritin January 2022 through December 2022, excluded white blood cell count (WBC > 9380 cells/μL) C-reaction protein (CRP 0.5 mg/dL). was measured by Sysmex XN-10 XN-20 hematology analyzer (Sysmex, Kobe, Japan). Serum Roche Cobas e801 (Roche Diagnostics, Mannheim, Germany). total binding capacity (TIBC) were c702 Anemia defined concentration <13 g/dL men < 12 women. <15 μg/L. Student T-tests Pearson correlation performed, P-values less than 0.05 considered statistically significant. Statistical analyses performed SPSS software (Version 22.0). Results A 2208 patient enrolled this classified into IDA, deficiency, anemia, control groups according level concentration. 20.6, 27.7, 30.4, 32.3 pg groups, respectively. IDA group showed significantly lower levels (P 0.001). By analysis, weak positive (r = 0.236, 0.274), moderate 0.354), negative TIBC −0.369). In addition, average turn-around time (received-reported) 16.4 min, shorter other biochemical markers such iron, (57.7, 34.2, 34.4 min). Conclusion an assessment actually used biosynthesis useful rapid tool diagnosing monitoring anemia.